MTOR and kaposiform hemangioendothelioma: Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has been extensively investigated for its therapeutic potential across a range of diseases and has achieved notable prominence in the management of kaposiform hemangioendothelioma (KHE) in recent years.